Article

Hotspot mutations in HER2 interfaces destabilize structure, causing breast cancer treatment failure

2025-03-20

Abstract excerpt

<title>Abstract</title> <p>Many HER2-positive breast cancer (BC) patients relapse within a year of trastuzumab or neratinib treatment. We identified specific pathogenic mutations in the dimerization domains II and IV of the HER2 receptor that contribute to treatment resistance. Mutations G309A, S310Y, and P523S induce significant structural alterations, disrupting crucial HER2:HER2 binding pockets. HER3-preferrin...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: f792764f-c0de-51a8-a63e-eebdb4bee4a1
DOI: 10.21203/rs.3.rs-5931887/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Hotspot mutations in HER2 interfaces destabilize structure, causing breast cancer treatment failureDOI 10.21203/rs.3.rs-5931887/v1Read

HER2 mutation as an emerging target in advanced breast cancer.Semantic proximity Read

Computational and Functional Analyses of HER2 Mutations Reveal Allosteric Activation Mechanisms and Altered Pharmacologic Effects.Semantic proximity Read

Activating HER2 mutations in HER2 gene amplification negative breast cancer.Semantic proximity Read

Acquired Secondary HER2 Mutations Enhance HER2/MAPK Signaling and Promote Resistance to HER2 Kinase Inhibition in Breast Cancer.Semantic proximity Read

Acquired secondary HER2 mutations enhance HER2/MAPK signaling and promote resistance to HER2 kinase inhibition in HER2-mutant breast cancerSemantic proximity Read

Dual Characteristics of Novel HER2 Kinase Domain Mutations in Response to HER2-Targeted Therapies in Human Breast CancerSemantic proximity Read

New Gain-of-Function Mutations Prioritize Mechanisms of HER2 ActivationSemantic proximity Read

HER2 therapy. HER2 (ERBB2): functional diversity from structurally conserved building blocksSemantic proximity Read

Activating HER3 mutations in breast cancerSemantic proximity Read

Prolonged Response to Trastuzumab in a Patient With HER2-Nonamplified Breast Cancer With Elevated HER2 Dimerization Harboring an<i>ERBB2</i>S310F MutationSemantic proximity Read

Human Epidermal Growth Factor Receptor 2 Alterations and Prognostic Implications in All Subtypes of Breast Cancers.Semantic proximity Read

Computational Engineering of a Therapeutic Antibody to Inhibit Multiple Mutants of HER2 Without Compromising Inhibition of the Canonical HER2Semantic proximity Read